Public Deliverables

Within EU-funded Horizon 2020 projects, ‘Deliverables’ are “outputs that must be produced at a given moment” during the project. This includes, for example, the project website itself, detailed information on the scientific progress of a specific task, a research manuscript, a special report, a technical diagram, a brochure, a software, or another important “building block”. As soon as such a deliverable has been completed, a detailed deliverable report is required to be submitted to the European Commission (EC). The reports of work packages (WPs) 1, 2, 3, 5 and 8 are confidential, but some reports of WPs 4, 6, and 7 are public. Once these public deliverable reports are ready, we make them available here, so feel free to view or download them as you like.

WP4 – Biobanking and determination of biomarkers from patient samples

• D4.6 Validation of biomarker of cell death and humoral inflammation (month 60)
• D4.7 Validation of biomarker of cellular inflammation, regeneration, and senescence (month 60)
• D4.8 Validation of metabolomic and genetic biomarkers (month 60)
• D4.9 Validation of biomarkers of mitochondrial function (month 60)

WP6 – Health economics, reimbursement, exploitation, and sustainability

• D6.1 Liver Helix set up – 2 MB
• D6.5 Helix populated with best stakeholders and using optimised profiling for each organisation to recommend suggested collaborations within and outside of A-TANGO – 2 MB
• D6.7 Manuscript on health economic analysis (month 60)
• D6.10 Patenting of G-TAK intellectual property (IP) (month 60)

WP7 – Dissemination, communication, and training

• D7.3 Go-online of the public project website  – 900 kb
• D7.4 Project brochure and professional templates  – 1 MB
• D7.5 Brochure to inform in brief about A-TANGO for participants involved in the clinical study  – 1 MB
• D7.6 First patient and layman event  – 1 MB
• D7.7 First Helix event targeted to industry end-users and investors – 4 MB
• D7.8 Second patient and layman event – 4 MB
• D7.9 Video explaining new knowledge on G-TAK in srAH and ACLF (month 57)
• D7.10 Consensus-conference for the use of G-TAK in subjects with steroid-resistant alcoholic hepatitis (srAH) and acute-on-chronic liver failure (ACLF) (month 58)
• D7.11 Second Helix event targeted to industry end-users and investors – 2 MB